Please sign in to follow a disease.
Neoplasm with perivascular epithelioid cell differentiation
MONDO:0006359A soft tissue neoplasm composed of perivascular epithelioid cells. Representative examples include angiomyolipoma, clear cell-sugar-tumor of the lung, and lymphangioleiomyomatosis.
Also known as: PEComa, neoplasm with perivascular epithelioid cell differentiation, perivascular epithelioid cell neoplasm, perivascular epithelioid cell tumour, tumor with perivascular epithelioid cell differentiation, tumour with perivascular epithelioid cell differentiation
1462 clinical trials for this condition and its sub-types, 8 tagged with Neoplasm with perivascular epithelioid cell differentiation itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Neoplasm with perivascular epithelioid cell differentiation
-
Lymphangioleiomyomatosis 11 trials
1 sub-type
- Lung lymphangioleiomyomatosis 0 trials
-
Angiomyolipoma 4 trials · 5 incl. sub-types
3 sub-types
- Kidney angiomyolipoma 4 trials Sub-types →
- Epithelioid type angiomyolipoma 0 trials
- Hepatic angiomyolipoma 0 trials
-
Benign PEComa 0 trials · 5 incl. sub-types
2 sub-types
- Kidney angiomyolipoma 4 trials Sub-types →
- Clear cell-sugar-tumor of the lung 1 trial
-
Lung PEComa 0 trials · 1 incl. sub-types
2 sub-types
- Clear cell-sugar-tumor of the lung 1 trial
- Lung lymphangioleiomyomatosis 0 trials
-
Lymphangiomyoma 0 trials
Most studied deeper sub-types
-
New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
Disease control Recruiting nowThis study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…
Phase 1/2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Personalized maintenance therapy: a smarter way to treat advanced cancer?
Disease control Recruiting nowThis phase II trial is testing whether continuing targeted therapy or immunotherapy based on a tumor's molecular profile can benefit patients with advanced solid tumors that have stopped responding to prior treatment. After an initial treatment period, patients whose disease is s…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Immune booster drug tested on rare cancers
Disease control Recruiting nowThis study is testing a drug called pembrolizumab in people with ultra-rare sarcomas, a group of very uncommon cancers. The drug works by releasing the immune system's brakes so it can attack cancer cells. Researchers want to see if it can shrink tumors or stop them from growing,…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Could a pill that blocks estrogen help fight rare uterine cancers?
Disease control Recruiting nowThis phase 2 trial is testing elacestrant, a pill that breaks down estrogen receptors, in 30 people with advanced uterine sarcomas that are fueled by estrogen. The goal is to see if the drug can shrink tumors or slow their growth. Participants must have tumors that strongly expre…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Scientists launch deep dive into rare sarcomas to unlock immune secrets
Knowledge-focused Recruiting nowThis study is collecting tumor and blood samples from 400 people with rare soft tissue sarcomas to learn how their immune system reacts to the cancer. Researchers will also track patients' health over time to see how the disease progresses. The goal is to find clues that could le…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC